2022 Areas of Abstract Submission

Submission of Abstracts in the following areas is encouraged:

  • Artificial Intelligence/Machine Learning
  • Big Data Science & Healthcare Analytics/Digital Health/Technology Platforms in Drug Development
  • Biologics & Therapeutic Proteins
  • Biomarkers/Pharmacogenomics/Precision Medicine
  • Biosimilars/Generics
  • Cell- and RNA/DNA-based Therapies
  • Clinical Pharmacology Education
  • Clinical Trials/General Drug Development Strategy & Practice
  • Combination Drug Development
  • COVID-19
  • Drug Interactions/Drug Metabolism/Transporters
  • Drug Safety/Pharmacovigilance
  • Innovative Statistical Methods/New & Adaptive Clinical Trial Designs
  • Interprofessional Communication/Collaboration
  • Model-informed Drug Development/Applications of Modeling & Simulation (PK/PD)/Pharmacometrics
  • Natural Product Development & Use
  • Novel Use of Therapeutics/Drug Repurposing
  • Pediatrics
  • Pharmacodynamics/Mechanism of Action
  • Pharmacoeconomics/Pharmacoepidemiology
  • Pharmacokinetics (including PopPK, ADME, biopharmaceutics)
  • Rare Diseases
  • Real-world Evidence in Decision Making/Therapeutic Drug Monitoring/Quality of Life
  • Regulatory Science/Risk Management/Legal Considerations
  • Special Populations in Clinical Trials & Clinical Practice (geriatrics, organ impairment, transgender, other)
  • Therapeutic Specialties
  • Translational Medicine/Physiological-based Pharmacokinetics/Systems Pharmacology/In Vitro/In Vivo Extrapolation
  • Women’s Health

Primary criteria for acceptance of Abstracts are:

  • Applicability to clinical pharmacology and translational medicine;
  • Innovation and scientific merit;
  • Relevance to ACCP's mission.

Each Abstract must contain:

  • A statement of purpose, innovation or hypothesis;
  • Description of methods and materials;
  • Data and results;
  • Interpretation, conclusion and significance.